AMAG AMAG Pharmaceuticals, stock Story

AMAG -  USA Stock  

USD 13.75  0.00  0.00%

AMAG Pharmaceuticals is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 6th of November 2020. The stock is in a buyout trend. AMAG Pharmaceuticals Average Equity is projected to increase significantly based on the last few years of reporting. The past year's Average Equity was at 468.67 Million. The current year Enterprise Value is expected to grow to about 756.5 M, whereas Revenue Per Employee is forecasted to decline to about 671.1 K. As many millenniums are trying to avoid healthcare space, it makes sense to digest AMAG Pharmaceuticals a little further and try to understand its current market patterns. Let's discuss the possibilities of AMAG Pharmaceuticals maintaining its debt level in December.
Published over six months ago
View all stories for AMAG Pharmaceuticals, | View All Stories
Will AMAG Pharmaceuticals (NASDAQ:AMAG) debt increase in December
The entity currently holds 307.89 M in liabilities with Debt to Equity (D/E) ratio of 1.23, which is about average as compared to similar companies. The firm has a current ratio of 1.61, which is within standard range for the sector. Our trade recommendation tool can cross-verify current analyst consensus on AMAG Pharmaceuticals and to analyze the company potential to grow in the future.
AMAG Pharmaceuticals, financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of AMAG Pharmaceuticals,, including all of AMAG Pharmaceuticals,'s outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of AMAG Pharmaceuticals, assets, the company is considered highly leveraged. Understanding the composition and structure of overall AMAG Pharmaceuticals, debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

Understanding AMAG AMAG Pharmaceuticals, Total Liabilities

AMAG Pharmaceuticals, liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. AMAG Pharmaceuticals, has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on AMAG Pharmaceuticals, balance sheet include debt obligations and money owed to different AMAG Pharmaceuticals, vendors, workers, and loan providers. Below is the chart of AMAG AMAG Pharmaceuticals, short long-term liabilities accounts currently reported on its balance sheet.
You can use AMAG Pharmaceuticals, financial leverage analysis tool to get a better grip on understanding its financial position

How important is AMAG Pharmaceuticals,'s Liquidity

AMAG Pharmaceuticals, financial leverage refers to using borrowed capital as a funding source to finance AMAG Pharmaceuticals, ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. AMAG Pharmaceuticals, financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between AMAG Pharmaceuticals,'s total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for AMAG Pharmaceuticals,, but it might be worth checking our own buy vs. sell analysis

Breaking down AMAG Pharmaceuticals, Indicators

AMAG Pharmaceuticals reported the previous year's revenue of 297.7 M. Net Loss for the year was (258.84 M) with profit before overhead, payroll, taxes, and interest of 177.7 M.

Liabilities Breakdown

208.8 M
Tax Liabilities
195.4 M
Current Liabilities
414.3 M
Long-Term Liabilities
Total Liabilities609.68 Million
Current Liabilities195.39 Million
Long-Term Liabilities414.29 Million
Tax Liabilities208.79 Million

Momentum Analysis of AMAG Pharmaceuticals suggests possible reversal in December

Latest semi deviation is at 2.42. As of the 1st of November, AMAG Pharmaceuticals owns the market risk adjusted performance of (14.42), and Coefficient Of Variation of 950.56. AMAG Pharmaceuticals technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to analyze nineteen technical drivers for AMAG Pharmaceuticals, which can be compared to its peers in the sector. Please confirm AMAG Pharmaceuticals jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if AMAG Pharmaceuticals is priced correctly, providing market reflects its prevailing price of 13.72 per share. Given that AMAG Pharmaceuticals has jensen alpha of 0.6513, we suggest you to validate AMAG Pharmaceuticals's latest market performance to make sure the company can sustain itself in the future.

Although other companies under the biotechnology industry are still a bit expensive, AMAG Pharmaceuticals may offer a potential longer-term growth to shareholders. All things considered, as of the 1st of November 2020, we see that AMAG Pharmaceuticals moves indifferently to market moves. The firm is overvalued with below average chance of bankruptcy within the next 24 months. Our latest 30 days Buy-Hold-Sell recommendation on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of AMAG Pharmaceuticals,. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to